Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

SKYE

Skye Bioscience Inc

Oct 23 • 12:15PM ET

4.86

Dollar change -0.08
Percentage change -1.62	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX PCRX ACAD BMRN MDGL PRGO XENE CRIS VNDA TBPH

| Held by: IWM VTI VXF YOLO IWN VTWO IWC IWO RSSL VFMV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.91	Insider Own	39.77%	Shs Outstand	30.34M	Perf Week	13.55%
Market Cap	147.45M	Forward P/E	-	EPS next Y	-1.17	Insider Trans	-4.23%	Shs Float	18.27M	Perf Month	21.20%
Income	-42.29M	PEG	-	EPS next Q	-0.25	Inst Own	43.37%	Short Float	6.65%	Perf Quarter	-17.63%
Sales	0.00M	P/S	-	EPS this Y	81.51%	Inst Trans	145.38%	Short Ratio	3.76	Perf Half Y	-62.18%
Book/sh	2.59	P/B	1.87	EPS next Y	-17.96%	ROA	-94.50%	Short Interest	1.21M	Perf Year	86.92%
Cash/sh	2.74	P/C	1.77	EPS next 5Y	-	ROE	-130.08%	52W Range	1.44 - 19.41	Perf YTD	78.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.94%	ROI	-57.98%	52W High	-74.96%	Beta	1.80
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	0.00%	Gross Margin	-	52W Low	237.50%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	6.07	EPS Y/Y TTM	49.18%	Oper. Margin	0.00%	RSI (14)	56.76	Volatility	13.20% 13.04%
Employees	11	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	18.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	74.45%	Payout	-	Rel Volume	0.40	Prev Close	4.94
Sales Surprise	-	EPS Surprise	-2.56%	Sales Q/Q	-	Earnings	Aug 09 AMC	Avg Volume	323.28K	Price	4.86
SMA20	19.37%	SMA50	-1.22%	SMA200	-40.54%	Trades		Volume	57,926	Change	-1.62%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Initiated	Scotiabank	Sector Outperform	$20
Sep-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-09-24	Initiated	Craig Hallum	Buy	$18
May-23-24	Initiated	Cantor Fitzgerald	Overweight	$21
Apr-12-24	Initiated	Oppenheimer	Outperform	$25

Oct-21-24 07:00AM	Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences (GlobeNewswire)
Sep-23-24 07:00AM	Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan (GlobeNewswire) +11.15%
Sep-03-24 07:00AM	Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer (GlobeNewswire)
Aug-26-24 07:00AM	Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences (GlobeNewswire) +15.29%
Aug-23-24 06:45PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.69%
07:00AM	Loading…
Aug-22-24 07:00AM	Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity (GlobeNewswire)
Aug-09-24 05:59PM	Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -9.42%
Jul-24-24 07:30AM	Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial of Nimacimab for Obesity (GlobeNewswire)
06:00AM	Skye Bioscience Hosts Virtual KOL Event, "Metabolic Rewiring with CB1 Inhibition," and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints (GlobeNewswire)
Jul-11-24 07:15AM	Skye Bioscience to Host Virtual KOL Event, Metabolic Rewiring with CB1 Inhibition, on July 24th (GlobeNewswire) +6.90%
07:00AM	Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab (GlobeNewswire)
Jul-03-24 07:00AM	Skye Bioscience Appoints Dr. Karen Smith to Board of Directors (GlobeNewswire)
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
07:00AM	Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-25-24 07:00AM	Skye BioScience Participating in Piper Sandler Virtual Obesity Day (GlobeNewswire) -6.19%
08:22AM	Loading…
Jun-10-24 08:22AM	Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail (FierceBiotech.com) -8.78%
07:00AM	Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program (GlobeNewswire)
Jun-03-24 07:00AM	Skye Bioscience to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-10-24 07:00AM	Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting (GlobeNewswire) -6.21%
May-07-24 11:59AM	Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program (News Direct)
Apr-30-24 07:00AM	Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting (GlobeNewswire)
Apr-23-24 07:00AM	Skye Bioscience to Present at Upcoming Investment Conferences (GlobeNewswire) -5.27%
Apr-10-24 08:00AM	Skye Bioscience Uplists to The Nasdaq Global Market (GlobeNewswire) +39.69%
Mar-11-24 09:20AM	Skye Bioscience Announces $40 Million Private Placement Equity Financing (Newsfile) -24.95%
Mar-04-24 07:00AM	Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors (GlobeNewswire) +7.59%
Feb-26-24 07:00AM	Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension (GlobeNewswire) +13.82%
Feb-07-24 07:00AM	Skye Bioscience to Present at Oppenheimer Investor Conference (Newsfile) -7.55%
Jan-29-24 08:00AM	Skye Bioscience Announces $50.25 Million Private Placement Equity Financing (Newsfile) +29.03%

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schwab Andrew J.	Director	Sep 11 '24	Sale	6.60	252,500	1,666,500	66,356	Sep 13 06:56 PM
Schwab Andrew J.	Director	Sep 13 '24	Sale	6.06	13,837	83,852	66,277	Sep 13 06:56 PM
5AM Partners VII, LLC	10% Owner	Sep 11 '24	Sale	6.60	252,500	1,666,500	66,356	Sep 13 06:54 PM
5AM Partners VII, LLC	10% Owner	Sep 13 '24	Sale	6.06	13,837	83,852	66,277	Sep 13 06:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SKYE

Skye Bioscience Inc

Upgrade your FINVIZ experience